5MPN is a first-in-class, orally active, and selective inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4); it acts as a competitive inhibitor at the F6P binding site (Ki = 8.6 μM) and does not inhibit PFK-1 or PFKFB3; it targets tumor glycolysis and suppresses the proliferation of multiple human cancer cell lines.